Table of Content
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing sedentary lifestyle and expanding diabetes prevalence
4.1.1.2. The market will also be driven by reimbursement and other pricing-related government regulations
4.1.2. Restraints:
4.1.2.1. Limited pharmaceutical choices and lack of information on insulin resistance
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter’s Five Forces Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
5.4 Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Biguanides
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Glucagon-like Peptide 1 (GLP-1) Receptor Agonists
7.4. Concentrated Insulin Products
7.5. Sodium-glucose cotransporter 2 (SGLT2) inhibitors
7.6. Dipeptidyl peptidase-4 (DPP-4) inhibitor
7.7. Others
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Branded
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Generics
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Products Benchmarking
11.4. List of Key Companies to Watch
12. Company Profiles
12.1. Glenmark Pharmaceuticals
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. AstraZeneca
12.3. Bristol-Myers Squibb
12.4. Eli Lilly and Company
12.5. Merck & Co.
12.6. Nova Nordisk
12.7. Teva Pharmaceuticals
12.8. Sanofi
12.9. GlaxoSmithKline
12.10. Mylan.
LIST NOT EXHAUSTIVE
13. Global Insulin resistance Market – DataM
13.1. Appendix
13.2. About Us and Application
13.3. Contact Us